Month: June 2018

Specialised training session for H2020 project managers

On June 21st, the training session “How to support researchers in writing competitive proposals for Horizon 2020” was held at the Duran i Reynals hospital. The course, part of the ICABELL project, was taught by Dr. Sean McCarthy, expert in European funding for research projects.   The session, which had a high degree of attendance, …

Specialised training session for H2020 project managers Read More »

CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy

Cisplatin is one of the chemotherapeutic agents more frequently used by oncologists to treat tumors. Cisplatin-based chemotherapy is very efficient but frequently cancer cells adjust its molecular mechanisms to become resistant to cisplatin. The IDIBELL research group “Modeling Human diseases in C. elegans”, led by Julián Cerón, have been using a microscopic worm to investigate …

CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy Read More »

New discoveries towards the improvement of the immunotherapy treatment of lung cancer

In recent years, immunotherapy has been consolidated as one of the new and principal hopes in the fight against cancer. This therapeutic approach is based on the fact that our immune system is constantly watching the presence of strange presences within the body and fighting them. When a tumor originates, its mutations make cancer cells …

New discoveries towards the improvement of the immunotherapy treatment of lung cancer Read More »

New drug against of the main types of lung cancer

The clinical application of an inhibitor of the SHP2 protein (also called PTPN11) could be effective, in the near future, in patients affected by one of the main types of lung cancer, the so-called Non-small cell lung cancer (NSCLC). This is the conclusion reached by an international research team including doctors Alberto Villanueva and Ernest …

New drug against of the main types of lung cancer Read More »

New epigenetic drug against Mantle Cell Lymphoma

A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by …

New epigenetic drug against Mantle Cell Lymphoma Read More »

Scroll to Top